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Giardia intestinalis is a microaerophilic protozoan that is an important etiologic agent
of diarrhea worldwide. There is evidence that under diverse conditions, the parasite is
capable of shedding extracellular vesicles (EVs) which modulate the physiopathology of
giardiasis. Here we describe new features of G. intestinalis EV production, revealing its
capacity to shed two different enriched EV populations: large (LEV) and small extracellular
vesicles (SEV) and identified relevant adhesion functions associated with the larger
population. Proteomic analysis revealed differences in proteins relevant for virulence
and host-pathogen interactions between the two EV subsets, such as cytoskeletal and
anti-oxidative stress response proteins in LEVS. We assessed the effect of two recently
identified inhibitors of EV release in mammalian cells, namely peptidylarginine deiminase
(PAD) inhibitor and cannabidiol (CBD), on EV release from Giardia. The compounds
were both able to effectively reduce EV shedding, the PAD-inhibitor specifically affecting
the release of LEVs and reducing parasite attachment to host cells in vitro. Our results
suggest that LEVs and SEVs have a different role in host-pathogen interaction, and that
treatment with EV-inhibitors may be a novel treatment strategy for recurrent giardiasis.
Keywords: extracellular vesicles (EVs), large vesicle-like structures, small vesicles, PAD inhibitors, cannabiol,
diarrhea, Giardia intestinalis, parasite host cell-interaction
INTRODUCTION
Giardia intestinalis is a lumen dwelling pathogen in the vertebrate gut which is responsible for a
worldwide waterborne diarrhea known as giardiasis. It affects millions of people worldwide and
remains a neglected disease (Savioli et al., 2006; reviewed by Ankarklev et al., 2010; Cernikova
et al., 2018). The life cycle of this flagellated parasite consists of two evolutionary stages: (i) the
Gavinho et al. Giardia EV-Inhibitors: Cl Amidine and CBD
trophozoite, which adheres to the intestinal epithelium and
multiplies by binary fission, and (ii) the infectious stage,
the cyst, that is released through feces and is acquired by
ingestion of food or water. Giardia has a simple cell biology,
lacking organelles and a typical endosomal sorting complex
required for transport, the ESCRT (Saha et al., 2018). The
parasite accesses nutrients through specialized structures called
peripheral vesicles (PV), and the secretion of cyst wall proteins
is operated by the encystation-specific vesicles (ESVs) which
are absent in non-encysting trophozoites (Gottig et al., 2006).
The virulence factors involved in Giardia pathogenesis have
been described, including the cysteine proteases, which have
been well-studied. These are involved in intestinal epithelial
junctional complex disruption and degradation of host immune
factors, e.g., cytokines (Bartelt and Sartor, 2015; Cotton et al.,
2015; Liu et al., 2018). The parasite is also capable of evading
the adaptive immune defense through antigenic variation
(Prucca et al., 2008; Serradell et al., 2016). Yet, pathogenesis
remains to be fully understood. Finally, chronic infection is
a significant concern in giardiasis, as it represents nutritional
implications for children and immunocompromised individuals
(Halliez and Buret, 2013; Bartelt and Sartor, 2015).
Adaptions by protozoans for survival in the host involve
sophisticated forms of host-pathogen communication (Cipriano
and Hajduk, 2018). Importantly, many reports have described
the release of extracellular vesicles (EVs) from pathogens to be
relevant to the disease status (Cwiklinski et al., 2015; Coakley
et al., 2017). EVs are found in most biological fluids and are
30–1,000 nm lipid-bilayer vesicles, which are shed from cells and
transport a range of biomolecules, including protein and genetic
material, participating in cell communication in physiological
and pathophysiological processes (Coakley et al., 2015; Nawaz
et al., 2016; Maas et al., 2017; Ramirez et al., 2018; Ryu et al., 2018;
van Niel et al., 2018).
Our group has previously described EV release of
G. intestinalis and established that giardial EVs are involved
in host-pathogen interactions via immunomodulation and
trophozoite persistence (Evans-Osses et al., 2017). In addition,
Ma’ayeh et al. (2017) recovered EVs from the secretome of
an axenic culture. In recent years, there has been a growing
interest in improving the current knowledge of the nature,
constitution, and biogenesis of all secreted EVs. In the last few
decades, the term “exosomes” was proposed to refer to smaller
EVs (sEVs) of multivesicular bodies origin (<100 nm diameter).
Concomitantly, larger EVs (LEVs) called “microvesicles” (∼100–
1,000 nm) are released directly from the plasma membrane
(Tkach et al., 2018; Mathieu et al., 2019). Lately, the field of
EVs has debated the need to accurately separate EV subtypes to
investigate functional relevance (Tkach et al., 2018). There are
current limitations in techniques that analyze EVs and possibly,
a relation of size and biological function is an appropriate step
toward characterization (Moyano et al., 2019). Enrichment
of subpopulations of EVs from samples is acquired based
on differential centrifugation steps: large EVs (LEVs) are
obtained at speeds lower than 20,000× g and small EVs (SEVs)
are pelleted at 100,000 × g in a further ultracentrifugation
step. Formerly, microvesicles and exosomes, particularly
present in LEV and SEV, respectively, are considered the main
EV subpopulations. Exosomes are the smallest population,
continually produced in the late endosome and liberated through
the fusion of multivesicular bodies within the plasma membrane.
Microvesicles are particles of a larger size produced though
budding from the plasma membrane under stress mediated
by scramblase, calpain, and Ca2+ liberation (Morrison et al.,
2016; Nawaz and Fatima, 2017). Different roles for these EV
subpopulations remain a focus of ongoing investigations; are all
EVs phenotypically relevant and/or similar?
While it is known that EVs are released by multiple
mechanisms, some advances in the understanding of their
biogenesis has been elucidated via studies on the peptidylarginine
deiminase (PAD)-mediated pathway of EV release in diverse taxa
(Kholia et al., 2015; Kosgodage et al., 2017, 2018a, 2019a; Lange
et al., 2017). PADs are phylogenetically conserved enzymes from
bacteria to mammals (Vossenaar et al., 2003; Magnadottir et al.,
2018; Kosgodage et al., 2019a), including in Giardia (arginine
deiminase GiADI; Trejo-Soto et al., 2016). PADs catalyze post-
translational deimination by irreversibly changing arginine into
citrulline in a calcium-catalyzed manner in target proteins,
affecting their folding and function (Vossenaar et al., 2003;
György et al., 2006). PADs are involved in pathophysiological
processes and their up-regulation and associated increase in
deiminated proteins is associated with various pathologies
including autoimmune and neurodegenerative diseases, as well
as cancer (Vossenaar et al., 2003; Wang and Wang, 2013;
Witalison et al., 2015; Lange et al., 2017; Kosgodage et al., 2018a;
Uysal-Onganer et al., 2020). While exact roles for PADs in
EV biogenesis and release remain to be fully elucidated, effects
on cytoskeletal, nuclear, and mitochondrial proteins have been
reported (Kholia et al., 2015; Kosgodage et al., 2018a; Uysal-
Onganer et al., 2020). As pharmacological PAD-inhibitors have
previously been shown to be potent inhibitors of EV release
in various cancer cells and in bacteria, and modulators of
EV cargo (Kholia et al., 2015; Kosgodage et al., 2017, 2018a,
2019a), we sought to investigate a phylogenetically conserved
influence of PAD-inhibitors on the EV production of our
parasite model.
In addition, cannabidiol (CBD), a phytocannabinoid derived
from Cannabis sativa (Mechoulam et al., 2002), was recently
identified as a potent EV-inhibitor in cancer cells as well
as in bacteria (Kosgodage et al., 2018b, 2019b,c), indicating
a phylogenetically conserved function in EV regulation. As
cannabinoids have previously been associated with anti-parasitic
functions (Nok et al., 1994; Croxford et al., 2005; Roulette et al.,
2016) and the reduction of bacterial antibiotic resistance via
the inhibition of bacterial EVs/MVs (Kosgodage et al., 2019c),
we sought to identify whether EV release from Giardia may be
affected by CBD, thus elucidating a novel aspect of CBD function
on Giardia-host interaction.
Here, we report that G. intestinalis produces two populations
of EVs that differ in size. The larger EV population had a
significant effect on parasite-host adhesion in vitro and was
significantly reduced by both PAD-inhibitor and CBD. In
addition, treatment with PAD-inhibitor selectively prevented
parasite LEV production.
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METHODS
G. intestinalis Isolates and Cell Culture
G. intestinalis isolate WB (ATCC 50803) were grown in TYI-
S-33 medium (Keister, 1983) supplemented with 10% heat-
inactivated adult bovine serum with 1% Penicillin/Streptomycin
1000U (GibcoTM) and 0.5 mg/ml bovine bile (ThermoFisherTM)
at 37◦C under microaerophilic conditions. The cultures were
maintained in polystyrene tubes (BD BiosciencesTM) (13mL)
until confluence (1 × 106 cells mL). and thereafter sub-
cultured, each for 72 h. Human colorectal adenocarcinoma cells,
Caco-2 cells (ATCC CRL-2102) were cultured in RPMI-1640
supplemented with 10% fetal bovine serum, 2mM r-glutamine,
and 1% Penicillin/Streptomycin 1000U (GibcoTM). Cells were
incubated at 37◦C in 5% CO2 until a confluent cell monolayer
was reached.
EV Isolation
For parasite EV isolation, parasites from confluent culture tubes
were detached by chilling for 15min on ice, centrifuged twice
(600 × g/5min) and the pellets suspended with fresh TYI-
S-33 without adult bovine serum (ABS). Parasites were then
counted using a hemocytometer, and diluted to 1 × 106 per
sample according to Evans-Osses et al. (2017). Samples were
distributed to 1.5mL microtubes (final volume of 1mL) and
1mM of CaCl2 was added for EV induction and the tubes were
then incubated for 1 h at 37◦C. Then, EV pellets were collected
via step-wise centrifugation: first, at 600 × g/5min; 4,000 ×
g/30min to eliminate cellular debris, thereafter the supernatant
was centrifuged at 15,000 × g for 1 h and the resulting pellet
(LEV) was resuspended in phosphate buffered saline (PBS). The
remaining supernatant was then ultracentrifuged for 100,000 ×
g for 4 h, and the resulting EV-containing pellets (SEV) were
resuspended in PBS (1x). Both samples were kept at 4◦C until
further use.
For mammalian EV purification, Caco-2 cells were cultured in
T25 flasks until confluence, and then the medium was removed.
Cultures were washed twice with fresh RPMI-1640 and kept for
1 h with medium omitting ABS, to avoid contamination of EVs
from ABS. The supernatant was processed in the same manner
as described for the parasite. EVs were stored at 4◦C until further
use for host-pathogen interaction assays.
EV Quantification and Characterization
EVs were in the first instance quantified based on their protein
concentrations using the Micro BCA assay (ThermoFisherTM).
For Nanoparticle tracking analysis (NTA, Nanosight, Malvern,
U.K.), each sample was diluted 1:100 in PBS (1x) and subjected to
a NS300 Nanosight (MalvernTM, U.K.), with readings performed
in triplicate during 60 s videos at 10 frames per second at
room temperature, with the following parameters: camera
shutter −1492, camera gain −512, detection threshold −10. The
resulting replicate histograms were averaged for presentation
in box-plots.
Treatment of Trophozoites With
EV-Inhibitors
Inoculum of 106 trophozoites per group (triplicates) were
stimulated with 1mM CaCl2 in 1.5mL microtubes for the
production of EVs, with or without EV-inhibitors. Experimental
groups were as follows: medium only (control), 100 or 50µM
PAD-inhibitor Cl-amidine (a kind gift fromProf Paul Thompson,
UMASS), or with 5 or 10µM CBD (90899_SIAL, Sigma-
AldrichTM). After 60min of incubation (37◦C), supernatants
were processed following the protocol described above for
EV isolation.
Trophozoites Growth Curves
A growth curve was generated from the parasites submitted to
vesiculation at different time intervals (1, 3, or 6 h).
Inoculums of 100 µL at 1 × 105 trophozoite/mL from each
group were resuspended in a complete TYI-S-33 medium, added
to polystyrene culture tubes, and maintained at 37◦C, for an
overall time period of 96 h. Every 24 h, the tubes were chilled on
ice for 15min to promote trophozoite detachment, and aliquots
of 10 µL were subsequently taken from the culture tubes to
count Giardia trophozoites on a hemocytometer under a Bioval
optical microscope.
Following the protocol described above, we also maintained
growth curves from trophozoites treated with Cl-amidine
(100µM), Cannabidiol (CBD) (10µM), and WT (control).
Host-Pathogen Interaction Assay Exposed
to EV-Inhibitors
Caco-2 cells were seeded in 24-well plates and grown to 100%
confluence. Inoculations of 5 × 105 trophozoites per group
were transferred to the cell monolayer for 3 h (37◦C) in a final
volume of 1 mL/well. The following groups were investigated:
medium only (control), 10µM CBD, and 100µM Cl-amidine.
After incubation, trophozoite quantification was performed
by centrifuging non-adherent parasites from the supernatant
and counting them from the pellet using a hematocytometer.
The percentage of trophozoites adhering to Caco-2 cells was
subsequently calculated according to Cotton et al. (2014).
Experiments were also conducted with the two different EV
populations. In those cases, the co-cultures were treated with 7
or 14 µg LEVs and 7 or 14 µg SEVs. In order to understand
whether the EV-modulatory effect of Cl amidine or CBD was
affected by a Ca, Mg, or IP3 lysozome pathway, we performed
an independent experiment where we treated trophozoites with
chelating agents (5mM EDTA or EGTA), and an inhibitor of the
PI3K signaling pathway, wortmanin (100 nM). We have tried to
obtain preliminary findings to understand whether there might
be a synergism of these agents with either the Cl-amidine or CBD
inhibitor. As Cl-amidine was the more effective EV inhibitor,
we assessed the compounds only in the presence of 100µM Cl-
amidine. In a separate experiment, EVs were subjected to heat
inactivation (65◦C/30min), as described in Salomon et al. (2014),
and then used as negative controls of EVs to treat trophozoites
with or without exposure to Cl-amidine (100 µM).
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In independent experiments to assess the effects of
mammalian (Caco-2 derived) EVs on trophozoite adhesion, the
same host-pathogen interaction assay was used. Experimental
groups were as follows: 7 or 14 µg Caco-2 cell SEVs, 7 or 14 µg
Caco-2 cell LEVs, and the negative control with medium alone.
Influence of Protease Inhibitor on
Host-Pathogen Interaction
The influence of a protease inhibitor was assessed for parasite
adhesion to Caco-2 cells. For this, 5 × 105 trophozoites were
seeded into Caco-2 cell monolayers at 37◦C. The co-culture
was treated with 1mM iodoacetamide (IAA, cysteine protease
inhibitor), with or without 3.5 µg LEVs (3 h), and the negative
control with medium alone. Adhesion estimation was performed
as in the host-pathogen interaction assay.
Sample Preparation for
Mass-Spectrometry Based Proteomics
Ev preparations were resuspended in 8M Urea containing
a protease inhibitor cocktail (Sigma-Aldrich). Samples were
subjected to six cycles of freeze and thaw before being
quantified by a fluorometric assay using the QubitTM Protein
Assay Kit (Invitrogen, Carlsbad, CA) platform according to
the manufacturer’s instructions. A total of ± 100 µg proteins
were reduced with 10mM Dithiothreitol (DTT) at 30◦C for
45min, followed by alkylation of cysteine residues with 40mM
of iodoacetamide (IAA) for 30min at room temperature in
the dark. Thereafter, the samples were incubated with DTT
5mM for 15min at 30◦C. The samples were digested with
trypsin (Promega, Cat#: V5111) (1:50, Enzyme: Substrate) for
18 h at 30◦C. Following digestion, all reactions were acidified
with 10% (v/v) trifluoroacetic acid (1% v/v final concentration)
to stop proteolysis. The samples were centrifuged for 10min at
12,000× g to remove insoluble materials. The tryptic peptides
were desalted prior to LC-MS analysis using two C18 disks (3M
Empore TM C18 extraction disk) stage-tips.
Nanoflow Liquid Chromatography Coupled
to Mass-Spectrometry (nLC-MS/MS)
Analysis
The nLC-MS/MS analysis was performed using an Easy Nano
LC1000 (Thermo) HPLC coupled with an LTQ Orbitrap Velos
(Thermo), where 10 µL of the sample was applied using a 300
nL/min flow rate of Mobile phase A (5% ACN 0.1% formic acid)
in a C18 EASY-column (2 cm × 5µm × 100µm; 120 Å pore,
Thermo) and separated in a C18 PicoFrit PepMap (10 cm ×
10µm× 75µm; 135 Å pore, New Objective), over 105min using
a linear gradient 2–30% of mobile phase B (100% ACN; 0,1%
formic acid). The eluted peptides were ionized using electrospray.
The top 20 most intense precursor-ions with charge-state = 2
were fragmented using CID at 35 normalized collision energy and
10ms activation time. The MS scan range was set between 350
and 1,500 m/z, the MS scan resolution was 60.000, the MS1 ion
count was 1 × 10e6, and the MS2 ion count was 3 × 104. The
experiments were analyzed in biological triplicates.
Protein Identification
Raw files were imported to MaxQuant version 1.5.3.8 with
the Andromeda search machine and searched against the
Uniprot Giardia intestinalis strain ATCC 50803WB clone C6
database (November 28, 2019 release; 7,156 entries) with
20 ppm for MS/MS. The followed parameters were used:
carbamidomethylation of cysteine (57.021464 Da) as a fixed
modification, and oxidation of methionine (15.994915 Da) and
N-terminal acetylation protein (42.010565 Da) were selected as
variable modifications. Enzyme specificity was set to full trypsin
with a maximum of two missed cleavages. The minimum peptide
length was set to 7 amino acids.
EV Staining
For uptake assays, EVs were stained and tested with
carboxyfluorescein succinimidyl ester (CFSE, ThermoFisherTM),
or with the lipophilic dye PKH-26 (SigmaAldrichTM). For
CFSE labeling, 1 µL of the fluorescent dye was diluted with
both EV populations in 1mL PBS. For PKH-26, 2 µL of
the fluorescent dye were diluted in 1mL of diluent C and
both EV populations were diluted 1/40 in diluent C. Both
dilutions were mixed together at a volume ratio of 1:1. For both
fluorescent dyes, labeling was continued for 15min at room
temperature in the dark. The reaction was stopped by adding
1mL Fetum bovine serum, and samples were then washed in
PBS (1x), and ultracentrifuged at 15,000 × g for 1 h to obtain
LEVs and at 100,000 × g for 4 h for the collection of SEV,
as before.
Parasite EVs Uptake by Caco-2 Cells
Caco-2 cells were incubated on sterile coverslips at 37◦C
in 5% CO2 with 7 or 14 µg of PKH26-labeled giardial
EVs (ThermoFisherTM) for 1 h. Caco-2 cell monolayers were
also labeled for nuclei (DAPI, blue—ThermoFisherTM). After
incubation, the cells were washed three times in cold PBS (1x),
and fixed with 4% paraformaldehyde. Coverslips were washed
with PBS (1x) and mounted with 10 µl of a 50% glycerol
solution. Internalized EVs were detected by confocal microscopy
(Nikon A1R HD Multifoton Confocal). Images were processed
by Image J software (v. 1.48—open source, Schneider et al., 2012).
Fluorescence intensity of two images per sample was obtained in
a duplicate experiment, and corrected cellular fluorescence was
estimated as in McCloy et al. (2014).
Cytotoxicity Assay of EV-Inhibitors Toward
Caco-2 Cells
Caco-2 cells were seeded into a 96-well plate and grown at 37◦C
in 5% CO2 until confluence in RPMI-1640 medium containing
10% fetal bovine serum and 1% penicillin/streptomycin (10
000 UI). Cells were treated with 10µM albendazole (ABZ,
positive control), 100µM Cl-amidine or 10µM CBD, in a final
volume of 100 µL per well. After 48 h, wells were washed with
100 µL of PBS (1x). Cells were fixed with absolute methanol
(50 µL) for 10min, after which 50 µL of crystal violet 0.2%
in ethanol/water (2% V/V) were added to each tube. After
2min, the wells were exhaustively washed with 200 µL of
PBS (1x). Elution was made with a sodium citrate solution
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FIGURE 1 | Isolation and characterization of two distinct EV populations produced from Giardia intestinalis. (A) The protocol for the isolation of LEVs and SEVs based
on differential centrifugation. (B) Quantification of vesicle numbers from nanoparticle tracking analysis (NTA). (C) Time-course for culture confluence of trophozoites
induced to produce EVs for 1, 3, and 6 h, respectively. (D,E) Particle size estimated by NTA for LEVs (D) and SEVs (E). Data are representative of at least three
independent experiments and represented as means ± SEM. ##P = 0.01, vs. the corresponding group, indicated by line; ns, not significant.
(0.05 µmol, 10min), and absorbance was determined at 540 nm
on a plate spectrophotometer, as described in Missina et al.
(2018).
Statistical Analysis
Statistical analysis of data was performed with GraphPad
Prism 6 Software using one or two-way ANOVA test. Values
are represented as means ± standard errors of the means
(SEM), acquired in biological triplicates. The normality of the
data was assessed prior to analysis. P = 0.05 were defined
as significant.
RESULTS
Giardia EV Biogenesis: Identification of
Two Distinct EV Populations
Two different EV sub-populations were isolated from
G. intestinalis. The previous protocol (Evans-Osses et al.,
2017) was slightly modified (addition of a 15,000× g step for 1 h,
increased ultracentrifugation time to 4 h) to separate putative
large extracellular (LEVs) and small extracellular vesicles (SEVs)
from the total EVs described before (Figure 1A). Using this
method, LEVs were recovered at 15,000× g and SEVs at 100,000
× g. Trophozoites were incubated with calcium chloride, an
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FIGURE 2 | EV-inhibitors Cl-amidine and CBD decrease the production of LEVs secreted from G. intestinalis. (A) EV protein quantification post-treatment with
Cl-amidine (Cl-am; 100 and 50µM) or CBD (10 and 5µM). (B) Host-pathogen assay concomitant to treatment with PAD-inhibitor (100µM) or CBD (10µM). (C)
Giardia EV concentration estimation by nanoparticle tracking analysis (NTA) post-treatment with 100µM Cl-am. (D) Particle analysis of the parasite distinct EV
populations [(A), EV size estimation of the distinct EV populations by NTA (nm); (B), yield particle/µg of protein obtained in 1 × 106 cells]. (E) Cytotoxic effects of the
EV-inhibitors on Caco-2 cell monolayers. Cells were incubated for 48 h with ABZ, Cl-am, and CBD at 10, 100, and 10µM, respectively, or with culture medium. Cell
viability was determined by the crystal violet method. (F) Effect of Cl-amidine in host-pathogen assay after treatment with EDTA (5mM), EGTA (5mM), and wortmannin
(WTN; 100 nM). Data are representative of at least three independent experiments and represented as means ± SEM. **P = 0.01, ***P = 0.001 compared to control
group (CTL). ##P = 0.01, ###P = 0.001; vs. the corresponding group, indicated by line.
enhancer of EV production. This protocol was performed for
parasite and mammalian host cells (Caco-2). Nanoparticle
tracking analysis (NTA; Figure 1B) showed a higher yield of
parasite EVs compared with Caco-2 cells (∼3-fold higher), as
also confirmed by protein detection (Supplementary Figure 1).
In addition, Giardia was found to be capable of shedding more
LEVs (∼3-fold higher) compared with SEVs. LEV and SEV
fractions showed a mean vesicle diameter of 187.6 and 67.7 nm,
respectively (Figures 1D,E). Growth assessment was performed
after stimulating trophozoites to produce EVs for 1, 3, and
6 h, respectively, following the growth curve in a complete
medium by 96 h at 37◦C in 5% CO2 (Figure 1C). There were no
significant differences observed on the growth-curve from the
different groups.
PAD-Inhibitor and CBD Treatment Affects
Giardia EV Biogenesis
G. intestinalis trophozoites were treated with the PAD-inhibitor
Cl-amidine or CBD, respectively, to assess the effects on EV
release. Both compounds were able to significantly reduce
production of EVs from Giardia (Figure 2A). In addition, we
assessed the ability to block host-pathogen interactions following
treatment with the EV-inhibitors. Indeed, both compounds were
capable of decreasing trophozoite adhesion to the Caco-2 cell
monolayer (Figure 2B).
We further assessed if Cl-amidine affected the release of SEVs
and LEVs equally. Concentration of LEVs by NTA estimated
a significant difference between treated compared to non-
treated groups (∼100-fold higher), while there was no difference
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observed for SEVs between treated vs. control non-treated
parasites (Figure 2C). The mean diameter (nm) of EVs released
in the presence of Cl-amidine was significantly reduced for LEVs
as follows: LEV (245.5), + Cl-am LEV (157.3), SEV (77.2), +Cl-
am SEV (99.8). Values of vesicles from each population, as well
as ratio particle/ug protein are shown in Figure 2D. EVs were
exposed to heat inactivation before treatment of co-cultures;
trophozoites treated with Cl-am and EVs showed a higher
attachment to Caco-2 cells when compared to parasites treated
with Cl-am and heat-inactivated EVs (Supplementary Figure 2).
We performed a toxicity test using mammalian cells, and
PAD-inhibitor or CBD had no cytotoxic effects at 48 h post-
treatment, compared with albenzadole, one of the common drugs
used for giardiasis treatment (Figure 2E). Trophozoites exposed
to the EV-inhibitors for 1 h in the vesiculation protocol were
resuspended in culture tubes and did not show any significant
difference in growth-curves, compared with the control culture
(Supplementary Figure 3).We furthermore treated trophozoites
with chelating agents (EDTA,a Ca2+/Mg2+ chelator, EGTA,Ca2+
chelator), and WTN (a PI3K inhibitor) in a host-pathogen assay.
These compounds did not affect parasite adhesion (Figure 2F).
LEVs Derived From Parasite, but Not Host
EVs, Restore the Lack of Adhesion to Host
Cells for G. intestinalis Trophozoites,
Treated With EV-Inhibitors
Due to the identification of the two EV populations, LEVs
and SEVs, in G. intestinalis, we sought to verify whether these
EV subpopulations had the same phenotype effect on host
cell adhesion. For this assay, two concentrations (7 or 14 µg)
from both EV populations, corresponding to the EV release
for this amount of parasite in in vitro vesiculation, were used.
LEVs derived from the parasite were capable of restoring the
adherence phenotype following treatment with Cl-amidine, in a
dose-dependent manner (Figure 3A). In contrast, no effect was
observed in the SEVs treated groups. These results suggest that
physical properties related to adherence can be found in the
larger Giardia EVs and therefore, EVs produced by the parasite
may selectively influence its phenotype.
We next assessed if the EVs from the host contribute to
the adherence process to host cells. Confluent Caco-2 cell
monolayers were washed and thereafter treated with Cl-amidine,
and trophozoites were added to the wells, followed by treatment
with Caco-2 cell-derived EVs (Figure 3B). Opposed to what was
observed for the trophozoite EVs, neither mammalian LEVs nor
SEVs had a phenotypical effect on trophozoite adhesion.
Moreover, we sought to investigate the influence of cysteine
peptidase inhibitors on parasite adhesion to Caco-2 cells,
treated with IAA. The cysteine protease inhibitor caused a
significant reduction in trophozoite adhesion to host cells
(Supplementary Figure 4) but this effect was reduced when the
parasites were incubated with LEVs from the parasites, indicating
that protease activity is not related to the effect on adhesion,
observed for EVs.
FIGURE 3 | Parasite derived EVs are selectively involved with Giardia
adhesion to host cells. (A) Adhesion assay following treatment with distinct
parasite EV populations and 100µM Cl-amidine. (B) Host-pathogen assay
after treatment of Caco-2 cell monolayer with Cl-amidine and incubation with
mammalian cell derived EVs. Data are representative of at least three
independent experiments and represented as means ± SEM. *P = 0.05,
**P = 0.01; compared to control group (CTL). #P = 0.05, ##P = 0.01; vs.
the corresponding group, indicated by line.
EVs Subtypes Contain Different Protein
Profiles
Proteomic analysis of SEVs and LEVs revealed some differences
in protein profiles (Supplementary Table 1). A total of 138
quantified proteins were identified in the LEV and SEV groups.
Seventy-seven proteins were identified only in the LEV group
and 19 proteins were exclusively found in the SEVs. Important
products related to the Giardia genre were found common to
both EVs, including antigenic Variable Surface Proteins (VSPs),
giardins, cathepsin B, and other virulence factors (arginine
deiminase, ornithine carbamoyltransferase).
There were 77 proteins exclusively found in LEVs
related to cytoskeleton composition and protein binding
(Figures 4A,B). Products identified in LEV are associated
with the cytoskeleton, as well as oxidative stress responses,
such as Peroxiredoxin-1 (Supplementary Table 2). SEVs
exclusively contained 19 proteins of which some related to
ribosome metabolism. Bioinformatic analysis of the Giardia
EVs proteome suggests the enrichment of enzymatic and
cytoskeletal products, metabolic processes, as well as stress
response to oxygen (Figure 5). Analysis of LEV and SEV
specific proteins revealed a distinct cellular sub-localization,
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 September 2020 | Volume 10 | Article 417
Gavinho et al. Giardia EV-Inhibitors: Cl Amidine and CBD
FIGURE 4 | EV subtypes derived from G. intestinalis differ in protein cargo. (A) Venn diagram of peptides identified in LEV and SEV. (B) Gene ontology for proteins
identified in LEV and SEV.
FIGURE 5 | Bioinformatic analysis of SEV and LEV proteins. (A) Protein-protein interaction networks. (B) Gene ontology. (C) Enriched metabolic pathways. (D) Pfam
domains identified in the total SEV and LEV protein datasets.
such as cytoplasm, nucleus, and plasma membrane, while SEVs
proteins were mostly cytoplasmic. Protein-protein interaction
and gene ontology analysis of LEV and SEV unique proteins
revealed different biological processes and different structural
domains (Figures 6A–C).
Host-Pathogen Interactions: Both SEV and
LEV Giardia Types Are Internalized by
Mammalian Cells
Giardia derived SEVs and LEVs were analyzed for their ability
to interact with host cells. Among the fluorochromes tested
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for EV labeling, only PKH-26 showed a homogeneous staining.
Both PKH26-labeled LEVs and SEVs were incubated with
Caco-2 cell monolayers for 1 h at two concentrations, 7 or
14 µg, respectively. Confocal microscopy revealed punctuated
patterns of fluorescence distributed intracellularly in Caco-2 cells
(Figure 7A). Both populations appeared to be taken up by the
host cells in a dose-dependent manner. Despite LEV intensity
internalization being observed to be higher overall, which may
relate to larger vesicle size (Figure 7B), final intracellular destiny
of the EVs was not determined.
DISCUSSION
The current study describes two distinct EV populations from
Giardia intestinalis where large EVs (LEVs), but not small EVs
(SEVs), were associated with effective parasite cell adhesion to
host intestinal cells (Caco-2) (Figure 3). A role for one of the
identified EV populations in host-pathogen interactions was
demonstrated, as treatment of G. intestinalis trophozoites with
pharmacological EV-inhibitors selectively decreased biogenesis
of LEVs (Figure 2). EV modulatory strategies have been
highlighted as an increasingly important approach in a range
of pathologies (Jorfi et al., 2015; Lange et al., 2017; Catalano
and O’Driscoll, 2020; Uysal-Onganer et al., 2020). Therefore, our
current findings highlight that such strategies in giardiasis may
be of considerable importance.
The pan-PAD-inhibitor Cl-amidine has previously been
described as a potent EV-inhibitor, compared to a range of
other compounds, in various cancer cells (Kosgodage et al.,
2017, 2018a), as well as to affect EV-mediated microRNA export
(Kosgodage et al., 2019a; Uysal-Onganer et al., 2020). Studies
have also shown that PAD-inhibitors can be strategically used
to sensitize cancer cells to chemotherapy (Kholia et al., 2015;
Kosgodage et al., 2017) and affect cancer cell invasion (Uysal-
Onganer et al., 2020). The effect of PAD-inhibitors on EV
release furthermore seems to be a phylogenetically conserved
pathway as PAD-inhibitors were also found to reduce EV release
from bacteria and accordingly, to effectively sensitize bacteria
to antibiotics (Kosgodage et al., 2019b). The EV-modulatory
functions of CBD were also recently revealed, and CBD has
even been found to be a more potent EV inhibitor than Cl-
amidine in some cancer cell types, also to have chemosensitizing
effects and showing selective inhibition on smaller or larger EVs
according to cancer type (Kosgodage et al., 2018b). Furthermore,
CBD was recently revealed to reduce bacterial EV release, modify
proteomic content of bacterial EVs, and to sensitize certain
bacteria to antibiotic treatment via this pathway (Kosgodage
et al., 2019c), indicating also a phylogenetically conserved
function for CBD in EV modulation. Such EV-modulatory
functions, as also observed in our current study in Giardia,
may correlate to the reported effects of cannabinoids as anti-
parasitic agents, where inhibitory effects on parasite invasion and
the immunosuppression of trypanosomiasis has been reported
(Nok et al., 1994; Croxford et al., 2005). Cannabinoids have
furthermore been shown to be effective anti-helmitics (Roulette
et al., 2016), while their effects on Giardia have hitherto not
been investigated. Our current findings may therefore be of
considerable interest for putative use of CBD in giardiasis.
The field of EV research is still rapidly growing, with
characterization of functions of subpopulations gaining increased
attention. The complex function of LEVs revealed here in
Giardia, suggests that their influence on phenotypes could be
even more diverse than those of SEVs (Tkach et al., 2018). No
biomarkers were considered in the present study, since both EV
populations are enriched mixtures of vesicles that fail to contain
any unique marker (Kalra et al., 2013; Vader et al., 2016) and
parasite cells may have different sets of markers in their genome
(Gonçalves et al., 2018; Ramirez et al., 2018).
Properties related to different functions of LEV have
been studied in non-infectious models. For example, LEVs
derived from cancer prostate cells contain substantially more
large size dsDNA than SEVs (Vagner et al., 2018). LEVs
(microvesicles) derived from platelets were also associated with
polymorphonuclear leucocytes increase in adhesion (Fujimi
et al., 2002). On the other hand, properties related to cellular
adhesion for SEVs isolated from two cancer cell lines have
also been identified while the same was not detected for LEVs
(Jimenez et al., 2019). LEVs identified in Fasciola hepatica
contained protein cargo related to digestion (cathepsin L1
zymogen), while proteomic and functional analyses identified
membrane structure components and immunomodulation
factors in SEVs (Cwiklinski et al., 2015).
EVs from Giardia have previously been studied in host-
pathogen interactions. Evans-Osses et al. (2017) identified that
LEVs (microvesicles) increase in vitro adhesion of trophozoites
in Caco-2 cells, and also increase the activation of immature
dendritic cells. Moyano et al. (2019) characterized a population
of SEVs (exosomes), and suggested that EV release depends on
ceramide and Rab11, despite parasite loss of ESCRT machinery.
According to Saha et al. (2018) the parasite ESCRT is localized at
the PV, the endolysosomal equivalent forGiardia.Wampfler et al.
(2014) conducted a proteomic analysis of specified-PV and ESV
content. The latter appears to assume a functional role similar to
the endoplasmic reticulum, such as recruitment of ribosomes to
organelle membranes (Wampfler et al., 2014). Benchimol (2004)
studied the release of ESVs on giardial cell surface. They detected
large granules docking in the plasma membrane. In addition,
Midlej et al. (2019) investigated the release of intraluminal
vesicles from trophozoites treated with CaCl2. Using electron
microscopy techniques, they demonstrated the exocytosis of
those vesicles and recovery in the supernatant. In another study,
a proteomic analysis of excretory-secretory products (ESP),
was conducted, including EVs of axenic cultures and cultures
of trophozoite interacting with mammalian cells, identifying
proteins related to metabolism, without signal peptides on EVs
(Ma’ayeh et al., 2017).
Our proteomic analysis of Giardia EVs detected relevant
virulence factors and immunogenic molecules such as cathepsin-
B, arginine-metabolizing enzymes, and VSPs in both EV
subpopulations. Many of the proteins found are associated with
parasite cytoskeleton, such as giardins, katanin, and ankyrin
repeat proteins. Due to the prominent role of proteins from
cytoskeletons in parasite adhesion and virulence, we propose that
Giardia adhesion to epithelial cells could be related to surface
molecules and Disk-associated proteins, identified here to be
contained in LEVs. These proteins are rich in ankyrin repeats
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FIGURE 6 | Protein-protein interaction, biological processes, and Pfam domains related to SEV and LEV exclusive proteins. Orange and purple color indicates
exclusive proteins identified in LEV and SEV, respectively. (A) Protein-protein interactions between the exclusive proteins of LEV and SEV. (B,C) Biological processes
and Pfam enriched domains are shown, respectively.
and may contribute to attachment, protein-protein interactions,
and stability (Weiland et al., 2005; Andersson et al., 2007;
Nosala et al., 2018; Hagen et al., 2020). Some of the giardins
detected in LEVs, such as the alpha-1 giardin, are capable of
binding to glycosaminoglycans present in the intestinal epithelial
monolayer, and hence can play a role in the early host–parasite
interplay (Weiland et al., 2003).
Giardia has to survive an unfriendly environment in the
small intestine, while it lacks mitochondria and a conventional
ROS-scavenging enzyme, such as catalase, superoxide dismutase,
and glutathione (GSH) peroxidase. Our proteome analysis also
suggests that EVs carry products associated with oxidoreductase
activity, such as Peroxiredoxin-1, FixW, and PFOR. These
products were also identified in the work of Ansell et al. (2016).
Ma’ayeh et al. (2015) investigated the transcriptome of Giardia
isolates in oxidative stress (O2, H2O2). Isolate GS revealed higher
levels of Peroxiredoxin-1 and other antioxidative products.
In another work from the same authors (Ma’ayeh et al., 2017),
a proteomic analysis of trophozoites incubated with intestinal
epithelial cells detected 11 proteins with oxidoreductase activity
in the WB isolate.
Our evidence of dose-dependent internalization of EVs,
together with proteomic data on cytoskeleton protein
enrichment, suggests that EVs may be associated with the
recovery of trophozoite adhesion capacity altered with the
PAD-inhibitor. Experiments with overexpression of genes
in trophozoites, to be released by vesicles as blockage with
monoclonal antibodies, could give an idea of whether the type of
interaction is specific and assess downstream effect on molecular
EV-cargo. Understanding the internalization and intracellular
destiny of EVs and EV subpopulations is a future challenge for
further in-depth studies.
While the majority of Giardia infected individuals are
asymptomatic, giardiasis is a major contributor to malnutrition
and growth impairment in children from developing countries
(Fink and Singer, 2017). Additionally, the disease may also last
for a long term chronic infection. Therefore, it is important
to identify and study novel clinical strategies that can lead
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FIGURE 7 | The two G. intestinalis EV sub-populations are efficiently taken up by Caco-2 cells. (A) Caco-2 cells incubated with PKH26-labeled LEVs or SEVs. (B)
Internalized EVs were quantified by means of fluorescence intensity. Background signal was subtracted for every single image before obtaining the fluorescence
intensity (Arbitrary Units); scale bars are indicated at 16µm. Data are representative of at least three independent experiments and represented as means ± SEM. #P
= 0.05, ##P = 0.01; vs. the corresponding group, indicated by line.
FIGURE 8 | G. intestinalis EV sub-populations have different protein content, and differentially restore adhesion of trophozoites following EV-inhibitor treatment.
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to host recovery. PAD-inhibitor Cl-amidine and CBD were
here shown to effectively decrease parasitic EV release, which
contributes to parasite adherence into intestinal epithelial cells
(Caco-2 cells). They may therefore pose as novel therapeutic
candidate agents for cases of chronic giardiasis.
CONCLUSION
Our results suggest that the two EV populations identified
in G. intestinalis so far, LEVs and SEVs, have distinct protein
content and functions in the phenotype of this pathogen
and can be selectively modulated using PAD-inhibitors and
CBD (Figure 8). Since adhesion in the epithelial intestine is
fundamental to parasite fitness and invasion, and LEVs clearly
aid this process, the use of targeted EV–inhibitors, such as Cl-
amidine identified here, can be used to selectively interfere with
EV secretion, allowing novel treatment strategies in the control
of giardiasis.
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PAD-inhibitors and EVs subjected to heat inactivation. Data are representative of
at least three independent experiments and represented as means ± SEM. #P =
0.05; vs. the corresponding group, indicated by line. ∗∗∗P = 0.001; compared to
control group (CTL).
Supplementary Figure 3 | Growth curve for culture confluence of trophozoite
after exposure to 100µM Cl-am or 10µM CBD, following 96 h incubation. Data
are representative of at least three independent experiments and represented as
means ± SEM. ns, not significant.
Supplementary Figure 4 | Host-pathogen assay treated with a protease inhibitor
and LEVs. Data are representative of at least three independent experiments and
represented as means ± SEM. #P = 0.05; vs. the corresponding group,
indicated by line. ∗∗P = 0.01; compared to control group (CTL).
Supplementary Table 1 | Proteomic content in SEVs and LEVs.
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